Added to YB: 2026-01-06
Pitch date: 2025-12-31
NVO [bullish]
Novo Nordisk A/S
+10.65%
current return
Author Info
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.5T
Pitch Price
DKK 329.00
Price Target
N/A
Dividend
3.36%
EV/EBITDA
9.64
P/E
14.86
EV/Sales
5.10
Sector
Pharmaceuticals
Category
growth
Our 10 Picks For 2026 - Novo Nordisk A/S
NVO: Global leader in diabetes/obesity care with blockbuster drugs Ozempic & Wegovy. 32.9% net profit margin, strong pipeline for long-term growth. Rising global obesity rates driving demand. Trading at cheapest valuation levels ever despite high profitability & growth prospects.
Read full article (1 min)